12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GS 1101: Phase III started

Gilead began the double-blind, placebo-controlled, international Phase III Study 116 trial to evaluate oral 150 mg GS-1101 twice daily in combination with rituximab in 160 previously treated CLL patients with measurable lymphadenopathy who have progressed less than 24 months after completing prior therapy...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >